Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14955738 | 1.00 | SYK (0.45) | SYKPDE4BTNIKMEN1KMT2A | |
| SCHEMBL14956599 | 0.93 | SYK (0.42) | SYKPDE4BTNIKALDH1A1 | |
| SCHEMBL14956596 | 0.93 | SYK (0.42) | SYKPDE4BTNIKALDH1A1 | |
| SCHEMBL14956135 | 0.88 | SYK (0.42) | SYKTLR8 | |
| SCHEMBL14956134 | 0.88 | SYK (0.42) | SYKTLR8 | |
| SCHEMBL14955298 | 0.85 | TRPV1 (0.43) | SYK | |
| SCHEMBL14955296 | 0.85 | TRPV1 (0.43) | SYK | |
| SCHEMBL14955874 | 0.85 | SYK (0.40) | SYK | |
| SCHEMBL14955872 | 0.85 | SYK (0.40) | SYK | |
| SCHEMBL14955555 | 0.83 | SYK (0.40) | SYKTNIKTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359308-B2 | Pyrazine kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | claimed |
| EP-2782579-B1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARM INC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-9359308-B2 | Pyrazine kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-8877760-B2 | Substituted pyrazine-2-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | ALEXION PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | SYK, ZAP70, LCK | SYK 1/4885PDE4B 1976/4885TNIK 30/4885 |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | SYK, ZAP70, LCK | SYK 1/4885PDE4B 1976/4885TNIK 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.